Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 407.42B | 400.28B | 367.53B | 322.13B | 285.27B | 255.64B |
Gross Profit | 87.53B | 89.40B | 86.87B | 77.59B | 67.33B | 65.50B |
EBITDA | 32.14B | 9.77B | 32.52B | 31.84B | 27.07B | 25.30B |
Net Income | 22.11B | 14.40B | 22.38B | 20.12B | 17.29B | 15.40B |
Balance Sheet | ||||||
Total Assets | 309.79B | 298.28B | 273.72B | 245.71B | 212.21B | 197.29B |
Cash, Cash Equivalents and Short-Term Investments | 34.29B | 29.11B | 29.63B | 27.91B | 23.91B | 19.78B |
Total Debt | 81.27B | 76.90B | 62.54B | 57.62B | 46.00B | 43.47B |
Total Liabilities | 204.62B | 195.69B | 174.80B | 159.36B | 135.73B | 126.75B |
Stockholders Equity | 95.04B | 92.66B | 88.76B | 77.77B | 71.76B | 65.49B |
Cash Flow | ||||||
Free Cash Flow | 24.86B | 20.70B | 25.68B | 23.40B | 19.89B | 20.12B |
Operating Cash Flow | 28.52B | 24.20B | 29.07B | 26.21B | 22.34B | 22.17B |
Investing Cash Flow | -14.26B | -20.53B | -15.57B | -28.48B | -10.37B | -12.53B |
Financing Cash Flow | -11.64B | -3.51B | -11.53B | 4.23B | -7.46B | -3.59B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
79 Outperform | $84.25B | 15.91 | 7.00% | 3.99% | 4.84% | -26.54% | |
77 Outperform | $28.93B | 16.95 | 10.09% | 1.45% | 10.09% | -12.18% | |
73 Outperform | $279.90B | 12.90 | 24.33% | 2.87% | 8.34% | 45.24% | |
71 Outperform | $16.81B | 5.03 | 12.59% | ― | 8.85% | 33.30% | |
71 Outperform | $85.42B | 17.72 | 12.37% | 1.88% | 24.65% | 48.38% | |
71 Outperform | $78.59B | 13.57 | 14.24% | 1.95% | 6.63% | -3.26% | |
64 Neutral | ¥342.56B | 10.47 | -2.86% | 2.57% | 11.81% | -7.17% |
On June 17, 2025, UnitedHealth Group agreed to sell various notes totaling $3 billion, with maturities ranging from 2028 to 2055, as part of an underwriting agreement with several major financial institutions. The issuance of these notes, registered under the Securities Act of 1933, is expected to impact the company’s financial strategy and market positioning by potentially enhancing liquidity and funding future operations.
The most recent analyst rating on (UNH) stock is a Buy with a $647.00 price target. To see the full list of analyst forecasts on UnitedHealth stock, see the UNH Stock Forecast page.
On June 2, 2025, UnitedHealth Group’s Board of Directors canceled performance-based restricted stock units for former CEO Andrew Witty following his retirement. During the same day, the company held its 2025 Annual Meeting of Shareholders, where nine directors were elected, executive compensation was approved, Deloitte & Touche LLP’s appointment was ratified, and a shareholder proposal on golden parachutes was rejected.
The most recent analyst rating on (UNH) stock is a Buy with a $647.00 price target. To see the full list of analyst forecasts on UnitedHealth stock, see the UNH Stock Forecast page.
On May 20, 2025, UnitedHealth Group’s Board of Directors accepted the resignation of Andrew Witty as a director, effective immediately. Consequently, Mr. Witty will not seek re-election at the upcoming annual shareholder meeting on June 2, 2025.
The most recent analyst rating on (UNH) stock is a Buy with a $647.00 price target. To see the full list of analyst forecasts on UnitedHealth stock, see the UNH Stock Forecast page.
On May 12, 2025, UnitedHealth Group announced that CEO Andrew Witty would step down, with Steve Hemsley taking over as CEO while continuing as Board Chair. The company also suspended its 2025 outlook due to higher-than-expected medical expenditures, with plans to return to growth in 2026.
The most recent analyst rating on (UNH) stock is a Buy with a $647.00 price target. To see the full list of analyst forecasts on UnitedHealth stock, see the UNH Stock Forecast page.